當前位置:文檔之家 > 醫學文獻翻譯(中英對照)

                  醫學文獻翻譯(中英對照)

                  The clinical and cost-effectiveness of Pharmalgen? for the treatment of bee and wasp venom allergy

                  1 TITLE OF PROJECT

                  The clinical and cost effectiveness of Pharmalgen? for the treatment of bee and wasp venom allergy

                  2 TAR TEAM

                  Liverpool Reviews and Implementation Group (LR i G), University of Liverpool Correspondence to:

                  Rumona Dickson, Ms

                  Director, LR i G

                  University of Liverpool

                  Room 2.12

                  Whelan Building

                  The Quadrangle

                  Brownlow Hill

                  Liverpool

                  L69 3GB

                  Tel: +44 (0) 151 794 5682

                  Fax: +44 (0)151 794 5585

                  Email: R.Dickson@http://www.jxjol.com/doc/27328915a216147917112816.html

                  For details of expertise within the TAR team, see section 7.

                  3 PLAIN ENGLISH SUMMARY

                  Allergic reactions to bee and wasp venom may occur in venom-sensitive patients immediately following a sting, and can vary in severity, with initially mild symptoms sometimes progressing to critical conditions within seconds. The most severe systemic allergic reactions (generalised reactions) are known as anaphylaxis, a reaction characterised by abnormally low blood pressure, fainting or collapse, and in extreme reactions these symptoms can cause death.

                  Each year in the UK there are between two and nine deaths from anaphylaxis caused by bee and wasp venom. The immediate treatment for severe allergic reactions to bee and wasp venom cons ists of emergency treatment with drugs to decrease the patient’s response to the venom and support breathing, if required.

                  To avoid further reactions, the use of sensitisation to bee and wasp venom, through a process known as venom immunotherapy (VIT), has been investigated. Venom immunotherapy consists of subcutaneous injections of increasing amounts of venom into patients with a history of anaphylaxis to bee and wasp venom. Pharmalgen? has had UK marketing authorisation for the diagnosis and treatment (using VIT) of allergy to bee venom (using Pharmalgen? Bee Venom) and wasp venom (using Pharmalgen? Wasp Venom) since March 1995, and it is used by more than 40 centres across the UK. This review aims to assess whether using Pharmalgen? in VIT is clinically useful when treating people with a history of severe reaction to bee and wasp stings. The review will compare preventative treatment with Pharmalgen? to other treatment options, including high dose antihistamines, advice on the

                  日本在线不卡免费av网站 - 视频 - 在线观看 - 影视资讯 - 品赏网